Biogen Inc. (BIIB) Stock

Biogen Inc. is a pioneering biopharmaceutical company dedicated to the discovery, development, and delivery of therapies targeting neurological and neurodegenerative diseases. Renowned for its comprehensive portfolio, Biogen offers innovative treatments across various therapeutic areas. These include multiple sclerosis (MS) therapies such as TECFIDERA, AVONEX, and TYSABRI, which address different aspects of MS management. The company also leads in the treatment of spinal muscular atrophy with SPINRAZA, transforming outcomes for patients with this rare genetic disorder.

Expanding its reach beyond MS and rare diseases, Biogen is advancing therapies for Alzheimer's disease with ADUHELM, aiming to address the urgent need for effective treatments in neurodegenerative conditions. Additionally, Biogen develops biosimilars like BENEPALI and FLIXABI, providing affordable alternatives to biologic medications for various inflammatory diseases. Its robust pipeline includes promising candidates targeting Alzheimer's disease, neuromuscular disorders, Parkinson's disease, and immunology-related conditions, reinforcing its commitment to advancing medical science.

Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen Inc. collaborates extensively with leading pharmaceutical companies and research institutions globally. These partnerships enhance its research capabilities and broaden its therapeutic offerings, underscoring Biogen's role as a leader in neurology and biotechnology. With a steadfast focus on innovation and patient-centric care, Biogen continues to shape the future of neurological treatments, striving to improve the lives of patients worldwide.